US Regulation of Pharmaceutical Outcomes Research Presented at the ISPOR 5th Annual International Meeting, Crystal City, VA, 24 May 2000  by Burke, Laurie B.
 Volume 4 • Number 1 • 2001
VALUE IN HEALTH
 




US Regulation of Pharmaceutical Outcomes Research
 
Presented at the ISPOR 5th Annual International Meeting, 
Crystal City, VA, 24 May 2000
 
Laurie B. Burke, RPh, MPH
 
Chief, Evidence Review Branch, Division of Drug Marketing, Advertising and Communications (DDMAC), 
 




 FDA, outcomes research, pharmaceuticals, regulation
O
 
utcomes research is a subset of clinical evalu-
ation that is increasingly being defined as a
separate scientific discipline. It produces informa-
tion that appears to be particularly attractive for
use in pharmaceutical product promotion. As a re-
sult, FDA frequently must determine when this in-
formation is adequate to support labeling and ad-
vertising claims. Discussion of outcomes evidence
is complicated by a lack of consistency in the ter-
minology used, but perhaps more importantly, by
a lack of understanding, and perhaps agreement
on, the evidentiary standards that should apply to
these data. FDA interacts with ISPOR and others
to clarify issues and facilitate policy development
in this area.
This lack of clarity is at least partly the result of
the very different but overlapping categories of
what appears to fall under the umbrella of outcomes
research, according to the focus of ISPOR and oth-
ers (Figure 1). Each category has its own special set
of scientific and regulatory issues. For example,
health-related quality of life (HRQL) is assessed in
ways similar to other clinical endpoints but poses
major problems because it usually assesses multi-
ple endpoints so that attaining consistent results is
difficult, and because the meaning of its results is
often not straightforward. On the other hand, eco-
nomic endpoints, although they can be measured
as clinical endpoints in trials, are often assessed us-
ing observational methods and models, and raise
special problems of generalizability.
Policy development for outcomes evidentiary
requirements is complex and case-specific, depen-
dent upon outcomes measurement, the disease, the
intervention, and population studied. This is par-
ticularly evident in the area of HRQL outcomes re-
search. Because the patient perspective is of great in-
terest to audiences who make decisions about using
drugs, pharmaceutical manufacturers commonly
seek to assess that perspective in their studies and
incorporate favorable findings in labeling and pro-
motion in the form of such claims as “improves
health-related quality of life,” “maintains health-
related quality of life,” “contributes to patient
well-being,” “meaningful survival,” and “expect a
bright future.” The first issue to be addressed when
reviewing claims such as these is what meaning
would be given to the claims by a recipient of the
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information. Would the claim lead a patient or a
physician to believe that the product will have the
subjective effect described, including well-being,
meaningful and bright? If so, the Federal Food Drug
and Cosmetic Act and its regulations require that





 of that effect.





, i.e., part of the way effects of a drug are
described to make them attractive in promotion.
Face validity can be adequate evidence for support
for such statements. For example, “convenient”
may be used to describe a product that is approved
for twice daily dosing when compared to a product
that requires four doses per day, as long as there is
no implication of superior effectiveness. The line
between puffery and claims that require substantia-
tion can be difficult to draw, however, as can be
seen in the above examples. In the case of “a bright
future,” if a product has been shown (with substan-
tial evidence) to have a survival benefit, must the
product also have been shown to increase the likeli-
hood that the future will be bright? Or, just by rea-
son of the fact that longer life can be expected can
one assume the future to be bright? The answer to
these questions depends on the disease or condi-
tion treated, the population indicated, and the drug.
If the statement represents a new claim, e.g., it ac-
tually uses the term HRQL, a more demanding re-
view is in order. In addition to the usual concerns
about design and analysis, there are special concerns
with the assessment instrument. The instrument is
scrutinized with all of its accompanying documen-
tation regarding development and validation. We
determine how instrument items, domains and scor-
ing algorithms were generated, and whether valid-
ity, reliability, and internal consistency have been
documented in a way that is appropriate for the
study design and population. Documentation of the
instrument’s linearity of response, responsiveness to
change and definitions of important change in score
are then reviewed in light of the study protocol.
An adequate study protocol will include details of
the instrument administration, blinding, and plans
for dealing with missing data. An adequate data
analysis plan is a critical point of the review, par-
ticularly in light of the multiple comparisons al-
most invariably generated in HRQL studies. It is
not unusual to see an analysis plan for the HRQL
endpoints that is fully separate—perhaps even an
appendix—from the primary efficacy endpoints.
This makes the possibility of finding significant
benefit remote, since only the most overwhelming
results could be persuasive. FDA has heard that
this situation results when the outcomes portion
of the study design is developed in a different area
of the company during product development. It
would behoove the company to consolidate all study
objectives and outcomes before completing the clini-
cal studies. Moreover, developing an HRQL end-
point needs the same sort of attention as any other
endpoint. Since it is not reasonable to imagine that
an intervention would affect all HRQL measures
similarly, it would be sensible to identify in ad-
vance the scales and subscales expected to re-
spond.
Once the existence of an adequate protocol is
determined, a thorough review of the study results
and interpretation of those results is possible. The
planned relationship between the HRQL endpoints
and the primary efficacy outcome is critical since,
without showing an effect on the primary efficacy
outcome (i.e., without demonstrating that the drug
works in the study population), it is doubtful that
a HRQL claim can be supported.
Even in the case of adequate instrument devel-
opment, validation, study protocol, data analysis
and interpretation, FDA often questions whether
the HRQL outcomes add to what we already
know about a product’s effects on symptoms and
functional status. If the overall result is driven by
the very effects already known for the drug, does
the HRQL language add anything at all? For ex-
ample, what is the added value of an outcome that
combines symptoms and functional status into a
single metric if we already know the drug’s impact
on the individual components? Isn’t it in fact more
informative to look at the symptoms? Further, apart
from reference to the instrument, what words can
be used to describe the results? Experts disagree
about whether an effect on one domain of an in-
strument (e.g., physical symptoms) can support a
claim if there is no impact on the overall HRQL
index. To further complicate the issue, how can a
claim such as “lead more active lives” be sup-
ported at all if no significant improvement is ob-
served on a related objective measure (e.g., exer-
cise tolerance). The HRQL scales that have been
used to date in labeling, such as the Asthma Qual-
ity of Life Questionnaire and the Minnesota Liv-
ing with Heart Failure scales, are primarily pa-
tient-derived physical disease severity scales, a
kind of HRQL scale to be sure, but much closer to
conventional symptom assessments.
Even though the multidimensional nature of
HRQL is fairly well accepted by experts in this
area of research, FDA has sometimes been pre-
sented with evidence from single-item questions to




support claims. In general, an effect on a single
item from an instrument will not provide credible
evidence of a benefit. A consistent effect on a de-
fined set of items (i.e., a domain) over several tri-
als, however, could be persuasive.
FDA has frequently objected to HRQL claims
that are supported only by studies that have sought
to demonstrate the impact or burden of disease on
HRQL without any assessment of the benefit of the
treatment. Companies have sought to imply that
the treatment will reverse this negative disease im-
pact. That sort of evidence cannot be expected to
meet the statutory requirements for a claim.
Two adequate and well-controlled studies are
generally required to support any clinical treat-
ment outcome claim. The purpose of this require-
ment is to ensure that the evidence is strong enough
to reach a conclusion and it not the result of chance
or bias. It would be very difficult to make a persua-
sive case for a study that was not double blind. In
addition, adequate validation of any measurement
instrument (including HRQL) includes assessment
of its measurement properties in a clinical trial set-
ting before using the instrument in a trial to dem-
onstrate a treatment effect. In many cases, the
HRQL instrument is not adequately validated be-
fore a clinical study (e.g., a phase III study) is un-
derway. In such cases, validation analyses can be de-
signed and added to the data analysis plan before the
study blind is broken. If the validation is adequate, a
second clinical trial may serve as confirmatory evi-
dence of a prospectively designated HRQL effect in
the first trial if both studies are rigorously designed.
Because of the developing nature of this field,
HRQL claims can be highly misleading unless they
are accompanied by full disclosure of the meaning
of the claim, the way the claim is supported, and the
limitations of the claim. FDA is addressing HRQL
issues on a case by case basis at the present time. As
experience accumulates and the field advances, the
Agency plans to issue guidance in this area. Until
FDA guidance is available, requests for advice on
development plans to support these outcomes are an-
swered as time permits. If a company asks for our re-
view of a study protocol, we can only review the plan
in light of the company’s intended labeling or adver-
tising claims. Advice is then specific to the proposed
claims and to the drug and condition reviewed.
Satisfaction and preference claims represent an-
other group of outcomes claims for which policy
is under development. FDA will object to a claim
such as “satisfied patients” or “preferred treatment”
unless it is supported by substantial evidence and
its meaning is clear. Patient testimonials, single-
arm studies, or surveys do not represent substantial
evidence for these outcomes. Experience with these
claims is growing, perhaps as a result of the need for
managed care organizations to compete for patients.
Study design principles that are specific to satisfac-
tion are emerging. At present, FDA reviews these
claims and their supporting evidence on a case by
case basis.
Another burgeoning area of outcomes research
and promotional claims review is productivity as-
sessment. Developing interest in this type of claim
in promotion seems to be related to the growing
attention of employers to the cost of prescription
drug benefits. Clinical trials sometimes incorpo-
rate productivity measures as secondary endpoints.
When using a productivity measure as a treatment
outcome, all the same concerns for instrument and
study adequacy discussed above apply. Productiv-
ity can also be an economic term, and when used
as an input to an economic model to produce cost
estimates, standards that are appropriate for eco-
nomic analyses would apply. The FDA Modern-
ization Act of 1997 amended the Federal Food
Drug and Cosmetic Act (FFDCA) by adding another
evidence standard specific to economic information
that is consistent with product approved indications
and is disseminated exclusively to formulary commit-
tees or similar entities. As for other developing out-
comes claims, FDA reviews economic claims and
their supporting evidence on a case by case basis.
The eventual development of guidance for such
claims will depend on whether regulatory need
and the FDA’s experience justifies such guidance.
The future of outcomes research in drug devel-
opment will be shaped by who the consumers of
outcomes information are and the perceived added
value of these outcome measures. It is likely that
clinicians, patients and managed care will eventu-
ally understand, embrace and demand data on some
of these outcome measures for use in their delib-
erative processes. In the meantime, development
of this field of research can benefit by integration
of outcomes researchers with the rest of the clini-
cal development team to facilitate production of
adequate evidence to meet developing regulatory
hurdles.
